A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age.
Latest Information Update: 05 May 2026
At a glance
- Drugs Chikungunya virus vaccine (Primary)
- Indications Chikungunya virus infections
- Focus Pharmacodynamics
- Sponsors Bharat Biotech
Most Recent Events
- 05 May 2026 New trial record